HIV1 Recombinant Adenoviral Vector Vaccine

Niaid Extramural Activities

Investigators

Linked publications & trials

Abstract

The work on this project was directed towards the development of a phase I, randomized, placebo-controlled, dose-escalation study of a multicomponent HIV-1 adenoviral vector vaccine. The hypothesis is that the vaccine will be safe for human administration and elicit immune responses to HIV-1. The proposed protocol design is to enroll subjects who will be randomly assigned to vaccine or PBS control injections. If there are no significant toxicities, dose escalation will be initiated.